CO2017003241A2 - Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante - Google Patents

Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante

Info

Publication number
CO2017003241A2
CO2017003241A2 CONC2017/0003241A CO2017003241A CO2017003241A2 CO 2017003241 A2 CO2017003241 A2 CO 2017003241A2 CO 2017003241 A CO2017003241 A CO 2017003241A CO 2017003241 A2 CO2017003241 A2 CO 2017003241A2
Authority
CO
Colombia
Prior art keywords
quinolinone
pyridin
derivatives
isocitrate dehydrogenase
dehydrogenase inhibitors
Prior art date
Application number
CONC2017/0003241A
Other languages
English (en)
Inventor
Susan Ashwell
Ann-Marie Campbell
Justin Andrew Caravella
R Bruce Diebold
Anna Ericsson
Gary Gustafson
David R Lancia
Jian Lin
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of CO2017003241A2 publication Critical patent/CO2017003241A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención se refiere a inhibidores de proteínas de isocitrato deshidrogenasa mutante (mt-IDH) con actividad neomórfica útiles en el tratamiento de trastornos de proliferación celular y cánceres, que tienen la Fórmula I
CONC2017/0003241A 2014-09-19 2017-04-03 Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante CO2017003241A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US201562150812P 2015-04-21 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
CO2017003241A2 true CO2017003241A2 (es) 2017-09-20

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0003241A CO2017003241A2 (es) 2014-09-19 2017-04-03 Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante

Country Status (36)

Country Link
US (8) US9834539B2 (es)
EP (4) EP3194376B1 (es)
JP (1) JP6648115B2 (es)
KR (1) KR102209667B1 (es)
CN (3) CN117695280A (es)
AU (3) AU2015317329B2 (es)
BR (1) BR112017005238B1 (es)
CA (1) CA2961817C (es)
CL (1) CL2017000658A1 (es)
CO (1) CO2017003241A2 (es)
CY (2) CY1121149T1 (es)
DK (2) DK3194376T3 (es)
EA (1) EA034336B1 (es)
EC (1) ECSP17022933A (es)
ES (3) ES2790640T3 (es)
FI (1) FI3733662T3 (es)
HR (1) HRP20200666T1 (es)
HU (2) HUE041460T2 (es)
IL (3) IL292608A (es)
LT (2) LT3194376T (es)
MA (2) MA40481A (es)
ME (1) ME03776B (es)
MX (2) MX2017003404A (es)
MY (2) MY197533A (es)
NZ (2) NZ730373A (es)
PE (1) PE20171056A1 (es)
PH (1) PH12017500517A1 (es)
PL (3) PL3733662T3 (es)
PT (3) PT3733662T (es)
RS (2) RS60140B1 (es)
SA (1) SA517381129B1 (es)
SG (1) SG11201702194SA (es)
SI (2) SI3447050T1 (es)
TW (1) TWI686390B (es)
WO (1) WO2016044789A1 (es)
ZA (2) ZA201702127B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) * 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
UA122121C2 (uk) 2014-02-06 2020-09-25 Хептерс Терап'Ютікс Лімітед Біциклічні азотовмісні сполуки як агоністи мускаринового м1 рецептора i/або м4 рецептора
KR20170049604A (ko) 2014-09-19 2017-05-10 바이엘 파마 악티엔게젤샤프트 Bub1 억제제로서의 벤질 치환된 인다졸
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
PL3733662T3 (pl) 2014-09-19 2024-01-22 Forma Therapeutics, Inc. Chinolinonowe pochodne pirydyn-2(1H)-onu jako inhibitory zmutowanej dehydrogenazy izocytrynianowej
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044782A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016106331A1 (en) * 2014-12-22 2016-06-30 The United States Of America Mutant idh1 inhibitors useful for treating cancer
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EP3619196B1 (de) 2017-05-04 2022-03-30 Bayer CropScience Aktiengesellschaft 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
SI3720442T1 (sl) 2018-05-16 2023-06-30 Forma Therapeutics, Inc. Zaviranje mutantnega IDF-1
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
US6921821B2 (en) 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
AU2008243674B2 (en) 2007-04-30 2013-02-28 Prometic Pharma Smt Limited "Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
CN102573485B (zh) 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012313888B2 (en) 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
CA2859985C (en) 2011-12-21 2020-11-03 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same
CN115536635A (zh) * 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
US20160039802A1 (en) * 2013-03-14 2016-02-11 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
SG11201605810WA (en) 2014-02-11 2016-08-30 Bayer Pharma AG Benzimidazol-2-amines as midh1 inhibitors
PL3733662T3 (pl) 2014-09-19 2024-01-22 Forma Therapeutics, Inc. Chinolinonowe pochodne pirydyn-2(1H)-onu jako inhibitory zmutowanej dehydrogenazy izocytrynianowej
EP3201185B1 (en) * 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044782A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016106331A1 (en) 2014-12-22 2016-06-30 The United States Of America Mutant idh1 inhibitors useful for treating cancer
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en) 2015-07-27 2019-10-30 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
JP6856657B2 (ja) 2016-02-26 2021-04-07 アジオス ファーマシューティカルズ， インコーポレイテッド 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤
EP3464281B1 (en) 2016-06-06 2020-07-08 Eli Lilly and Company Mutant idh1 inhibitors
ES2880347T3 (es) 2016-06-22 2021-11-24 Us Health Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer
LT3555105T (lt) 2016-12-16 2021-01-11 Eli Lilly And Company 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ono junginiai kaip mutantiniai idh1 ir idh2 slopikliai

Also Published As

Publication number Publication date
US20160083366A1 (en) 2016-03-24
US20180312487A1 (en) 2018-11-01
MX2017003404A (es) 2017-07-28
PL3447050T3 (pl) 2020-07-27
EP4257131A2 (en) 2023-10-11
EA201790657A8 (ru) 2018-02-28
PT3447050T (pt) 2020-09-17
EP4257131A3 (en) 2024-01-10
ECSP17022933A (es) 2017-08-31
SA517381129B1 (ar) 2021-04-26
RS60140B1 (sr) 2020-05-29
ES2704897T3 (es) 2019-03-20
CN107001328B (zh) 2020-06-05
ES2953347T3 (es) 2023-11-10
NZ730373A (en) 2019-11-29
DK3447050T3 (da) 2020-03-09
IL292608A (en) 2022-07-01
CN117695280A (zh) 2024-03-15
US20170174658A1 (en) 2017-06-22
US20240150319A1 (en) 2024-05-09
HUE062424T2 (hu) 2023-11-28
CA2961817A1 (en) 2016-03-24
ME03776B (me) 2021-04-20
EP3447050A1 (en) 2019-02-27
US10414752B2 (en) 2019-09-17
NZ758641A (en) 2023-12-22
JP6648115B2 (ja) 2020-02-14
KR20170063742A (ko) 2017-06-08
EA034336B1 (ru) 2020-01-29
US10550098B2 (en) 2020-02-04
BR112017005238A2 (pt) 2017-12-19
FI3733662T3 (fi) 2023-08-09
AU2019283765A1 (en) 2020-01-16
PL3733662T3 (pl) 2024-01-22
ZA201902446B (en) 2023-12-20
EP3733662B1 (en) 2023-06-07
TW201617335A (zh) 2016-05-16
CN107001328A (zh) 2017-08-01
IL251163B (en) 2021-05-31
PH12017500517A1 (en) 2017-08-07
US20190263778A1 (en) 2019-08-29
CA2961817C (en) 2024-03-12
ES2790640T3 (es) 2020-10-28
HRP20200666T1 (hr) 2020-07-24
US9834539B2 (en) 2017-12-05
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
CL2017000658A1 (es) 2017-12-22
HUE041460T2 (hu) 2019-05-28
CN111909130B (zh) 2023-10-31
SI3194376T1 (sl) 2019-03-29
IL282363A (en) 2021-06-30
AU2015317329B2 (en) 2019-10-31
RS58184B1 (sr) 2019-03-29
WO2016044789A1 (en) 2016-03-24
LT3194376T (lt) 2019-02-25
IL282363B (en) 2022-06-01
EP3447050B1 (en) 2020-02-19
EP3194376A1 (en) 2017-07-26
PT3733662T (pt) 2023-08-18
MX2019013203A (es) 2020-01-20
AU2021215141A1 (en) 2021-09-02
BR112017005238B1 (pt) 2023-01-17
PL3194376T3 (pl) 2019-05-31
TWI686390B (zh) 2020-03-01
PE20171056A1 (es) 2017-07-21
ZA201702127B (en) 2019-06-26
MY176250A (en) 2020-07-24
US20210078973A1 (en) 2021-03-18
MY197533A (en) 2023-06-21
LT3447050T (lt) 2020-05-11
IL251163A0 (en) 2017-04-30
CY1121149T1 (el) 2020-05-29
MA40481A (fr) 2017-07-26
EP3194376B1 (en) 2018-10-24
PT3194376T (pt) 2019-02-04
CN111909130A (zh) 2020-11-10
MA53352A (fr) 2021-09-15
AU2019283765B2 (en) 2021-05-13
JP2017528487A (ja) 2017-09-28
US20200223822A1 (en) 2020-07-16
US11498913B2 (en) 2022-11-15
DK3194376T3 (en) 2019-01-21
EA201790657A1 (ru) 2017-08-31
AU2015317329A1 (en) 2017-04-27
SG11201702194SA (en) 2017-04-27
US20230125739A1 (en) 2023-04-27
SI3447050T1 (sl) 2020-08-31
AU2021215141B2 (en) 2023-10-19
US10889567B2 (en) 2021-01-12
KR102209667B1 (ko) 2021-01-29

Similar Documents

Publication Publication Date Title
CO2017003241A2 (es) Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa mutante
ECSP16083602A (es) Derivados de quinolina como inhibidores smo
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
MX2017003637A (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
MX2017003626A (es) Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
GT201300260A (es) Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri)
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CY1117620T1 (el) Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
BR112014016146A8 (pt) derivados de imidazopiridina como um inibidor de tirosina quinase
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201992489A3 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
TWD169258S (zh) 蹦床